Living with Lung Cancer: A Journey of Hope and Understanding
Neal Augenstein’s journey with lung cancer has transformed his perspective, shifting from reporting on the disease’s devastating impacts to sharing insights on resilience and living with cancer. Diagnosed with Stage 4 non-small cell lung cancer in late 2022, Augenstein’s experience is a testament to the advancements in cancer treatment and the importance of patient education.
Initially, Augenstein’s career at WTOP involved covering stories about high-profile individuals who succumbed to lung cancer, the deadliest cancer in the United States. However, following his diagnosis, his focus shifted towards survival and the lessons learned throughout his treatment journey. Within six months of starting a targeted therapy that effectively reduced his tumors, he became eligible for a robotic-assisted lung lobectomy. Remarkably, since May 2023, he has experienced no evidence of disease, while continuing his daily medication.
A critical lesson from Augenstein’s experience is the significance of biomarker testing for newly diagnosed cancer patients. This process involves analyzing biopsied lung tissue to identify specific cell mutations that can inform treatment options. According to Dr. Ram Subramanian, a thoracic medical oncologist, understanding these mutations can lead to more effective treatments and improved patient outcomes. In Augenstein’s case, being diagnosed with EGFR-positive lung cancer opened doors to targeted therapies that typically result in fewer side effects compared to traditional chemotherapy.
Despite his current cancer-free status, Augenstein and his medical team remain cautious, acknowledging that he is not considered “cured.” His approach to living with lung cancer mirrors that of managing chronic illnesses like diabetes or heart disease, emphasizing the need for vigilant monitoring. This includes regular low-dose CT scans, brain MRIs, and liquid biopsies to detect any potential recurrences early.
The landscape of lung cancer treatment is evolving, with the American Lung Association reporting a five-year survival rate of 29.7% in 2025, reflecting a 26% improvement over the past five years. Innovations in research, including artificial intelligence, are enhancing early detection methods, providing hope for patients and their families.
For those in the D.C. area, access to numerous clinical trials offers additional avenues for treatment. Augenstein frequently discusses these options with his oncologist, Dr. Amin Benyounes, who leads the Phase One Program at the Inova Schar Cancer Institute. Many patients express concerns about the uncertainties of clinical trials, fearing adverse effects or the emotional toll on their loved ones. Dr. Benyounes encourages a step-by-step approach, reminding patients to take each day as it comes.
As Augenstein reflects on his journey, he emphasizes the importance of gratitude and the lessons learned along the way. His story serves as an inspiring reminder that with advancements in medical science and a proactive approach to treatment, living with lung cancer can be a journey of hope rather than despair. As he continues to share his experiences, he not only raises awareness about lung cancer but also fosters a sense of community and support for those navigating similar challenges.